PT1175489E - Oligonucleotidos contendo uma sequencia antisense estabilizada por uma estrutura secundaria e composicoes farmaceuticas contendo as mesmas - Google Patents

Oligonucleotidos contendo uma sequencia antisense estabilizada por uma estrutura secundaria e composicoes farmaceuticas contendo as mesmas

Info

Publication number: PT1175489E
Authority: PT; Portugal
Prior art keywords: secondary structure; antisense sequence; oligonucleotide; pharmaceutical compositions; same
Prior art date: 1999-03-09

Application number

PT00910916T

Other languages

English (en)

Inventor

Malvy Claude

Maksimenko Andrei

Helin Valerie

Gottikh Marina

Original Assignee

Inst Gustave Roussy Igr

Centre Nat Rech Scient

Bioalliance Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-09

Filing date

2000-03-09

Publication date

2006-10-31

2000-03-09 Application filed by Inst Gustave Roussy Igr, Centre Nat Rech Scient, Bioalliance Pharma Sa filed Critical Inst Gustave Roussy Igr

2006-10-31 Publication of PT1175489E publication Critical patent/PT1175489E/pt

Links

108091034117 Oligonucleotide Proteins 0.000 title abstract 6
230000000692 anti-sense effect Effects 0.000 title abstract 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
239000004480 active ingredient Substances 0.000 abstract 1
238000000338 in vitro Methods 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
239000002773 nucleotide Substances 0.000 abstract 1
125000003729 nucleotide group Chemical group 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Virology (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
AIDS & HIV (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

PT00910916T 1999-03-09 2000-03-09 Oligonucleotidos contendo uma sequencia antisense estabilizada por uma estrutura secundaria e composicoes farmaceuticas contendo as mesmas PT1175489E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9902921A FR2790757B1 (fr)	1999-03-09	1999-03-09	Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant.

Publications (1)

Publication Number	Publication Date
PT1175489E true PT1175489E (pt)	2006-10-31

Family

ID=9542992

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT00910916T PT1175489E (pt)	1999-03-09	2000-03-09	Oligonucleotidos contendo uma sequencia antisense estabilizada por uma estrutura secundaria e composicoes farmaceuticas contendo as mesmas

Country Status (12)

Country	Link
US (1)	US7022832B2 (pt)
EP (1)	EP1175489B1 (pt)
JP (1)	JP2004500018A (pt)
AT (1)	ATE328074T1 (pt)
AU (1)	AU3295700A (pt)
CA (1)	CA2363255A1 (pt)
DE (1)	DE60028367T2 (pt)
DK (1)	DK1175489T3 (pt)
ES (1)	ES2265916T3 (pt)
FR (1)	FR2790757B1 (pt)
PT (1)	PT1175489E (pt)
WO (1)	WO2000053745A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003006477A1 (en)	2001-07-12	2003-01-23	University Of Massachusetts	IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING
US20090005332A1 (en) *	2004-12-30	2009-01-01	Hauser Todd M	Compositions and Methods for Modulating Gene Expression Using Self-Protected Oligonucleotides
EP1934348B1 (en) *	2005-10-11	2018-05-02	Ben-Gurion University Of The Negev Research And Development Authority	Compositions for silencing the expression of vdac1 and uses thereof
US20100144831A1 (en) *	2006-09-27	2010-06-10	Habib Fakhral	Blocking of gene expression in eukaryotic cells
US7645578B2 (en) *	2006-10-31	2010-01-12	Agilent Technologies, Inc.	Cleavage of RNA at redundant sites
ATE508191T1 (de)	2006-11-01	2011-05-15	Medical Res And Infrastructure Fund Of The Tel Aviv Sourasky Medical Ct	Adipozytenspezifische konstrukte und verfahren zur hemmung der expression von blutplättchen-typ- 12-lipoxygenase
WO2010045384A2 (en) *	2008-10-15	2010-04-22	Somagenics Inc.	Short hairpin rnas for inhibition of gene expression
CN102264898B (zh)	2008-10-23	2013-10-16	国立大学法人东京大学	微小rna的功能抑制方法
US8871730B2 (en)	2009-07-13	2014-10-28	Somagenics Inc.	Chemical modification of short small hairpin RNAs for inhibition of gene expression
PT2933333T (pt) *	2010-07-08	2018-04-24	Bonac Corp	Molécula de ácido nucleico de cadeia simples para controlar a expressão génica
US8785121B2 (en)	2010-07-08	2014-07-22	Bonac Corporation	Single-stranded nucleic acid molecule for controlling gene expression
US8691782B2 (en)	2010-08-03	2014-04-08	Bonac Corporation	Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
CN109810977A (zh)	2012-05-26	2019-05-28	株式会社博纳克	具有递送功能的基因表达调控用单链核酸分子
EP2970965A2 (en) *	2013-03-15	2016-01-20	Pronai Therapeutics, Inc.	Dnai for the modulation of genes
CN105899663B (zh)	2013-12-26	2019-07-26	学校法人东京医科大学	用于基因表达控制的人工模拟miRNA及其用途
SG10201805087VA (en)	2013-12-27	2018-07-30	Bonac Corp	Artificial match-type mirna for controlling gene expression and use therefor
AU2015368293B2 (en)	2014-12-27	2021-07-22	Bonac Corporation	Naturally occuring miRNA for controlling gene expression, and use of same
HK1244031A1 (en)	2015-03-27	2018-07-27	Bonac Corporation	Single-chain nucleic acid molecule having delivery function and gene expression control ability
CN116262919A (zh)	2021-12-14	2023-06-16	成都凌泰氪生物技术有限公司	一种基于miRNA-2911的核酸分子
WO2025096807A2 (en) *	2023-10-31	2025-05-08	Flagship Pioneering Innovations Vii, Llc	Novel therapeutic dna forms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL172710B1 (pl) *	1992-07-02	1997-11-28	Hybridon Inc	Samostabilizujacy sie oligonukleotyd PL PL
GB2273932A (en) *	1992-11-24	1994-07-06	Stiefel Laboratories	Stable oligonucleotides
FR2703053B1 (fr) *	1993-03-26	1995-06-16	Genset Sa	Oligonucleotides agrafes et semi-agrafes, procede de preparation et applications .
US5631148A (en) *	1994-04-22	1997-05-20	Chiron Corporation	Ribozymes with product ejection by strand displacement

1999
- 1999-03-09 FR FR9902921A patent/FR2790757B1/fr not_active Expired - Fee Related
2000
- 2000-03-09 PT PT00910916T patent/PT1175489E/pt unknown
- 2000-03-09 WO PCT/FR2000/000586 patent/WO2000053745A1/fr not_active Ceased
- 2000-03-09 JP JP2000603366A patent/JP2004500018A/ja active Pending
- 2000-03-09 DE DE60028367T patent/DE60028367T2/de not_active Expired - Lifetime
- 2000-03-09 AU AU32957/00A patent/AU3295700A/en not_active Abandoned
- 2000-03-09 DK DK00910916T patent/DK1175489T3/da active
- 2000-03-09 EP EP00910916A patent/EP1175489B1/fr not_active Expired - Lifetime
- 2000-03-09 ES ES00910916T patent/ES2265916T3/es not_active Expired - Lifetime
- 2000-03-09 AT AT00910916T patent/ATE328074T1/de not_active IP Right Cessation
- 2000-03-09 CA CA002363255A patent/CA2363255A1/fr not_active Abandoned
2001
- 2001-09-07 US US09/949,134 patent/US7022832B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE60028367D1 (de)	2006-07-06
FR2790757A1 (fr)	2000-09-15
ATE328074T1 (de)	2006-06-15
EP1175489B1 (fr)	2006-05-31
JP2004500018A (ja)	2004-01-08
US20020156261A1 (en)	2002-10-24
CA2363255A1 (fr)	2000-09-14
AU3295700A (en)	2000-09-28
ES2265916T3 (es)	2007-03-01
EP1175489A1 (fr)	2002-01-30
DK1175489T3 (da)	2006-10-02
WO2000053745A1 (fr)	2000-09-14
WO2000053745A9 (fr)	2001-11-08
DE60028367T2 (de)	2007-02-08
US7022832B2 (en)	2006-04-04
FR2790757B1 (fr)	2003-08-01

Publication	Publication Date	Title
PT1175489E (pt)	2006-10-31	Oligonucleotidos contendo uma sequencia antisense estabilizada por uma estrutura secundaria e composicoes farmaceuticas contendo as mesmas
EP1798285B1 (de)	2017-03-15	Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
IL166546A (en)	2014-01-30	Double-stranded ribonucleic acid, preparations containing it, is used in drug preparation and in vitro method to inhibit the expression of a target gene
MX2008014100A (es)	2009-02-25	Compuestos y metodos para modular la expresion de pcsk9.
ATE416183T1 (de)	2008-12-15	Oligonukleotide mit alternierenden segmenten und deren verwendungen
ATE479752T1 (de)	2010-09-15	Therapeutische zusammensetzungen
DE69934227D1 (de)	2007-01-11	Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide
SG171676A1 (en)	2011-06-29	Compositions and methods for inhibiting expression of the pcsk9 gene
DK0731835T3 (da)	2002-10-28	Antisense-oligonukleotider med tumorigenicitetshæmmende virkning
WO2007056326A3 (en)	2009-09-24	Compositions and methods for inhibiting expression of nav1.8 gene
BR0108959A (pt)	2003-10-14	Composições de poloxmero ou poloxamina melhoradas para distribuição de ácido nucléico
WO2003101394A3 (en)	2004-11-11	Defensins: use as antiviral agents
WO2007137220A3 (en)	2008-07-31	Compositions and methods for inhibiting expression of ikk-b gene
EP1163373A4 (en)	2002-08-07	ANTISENSE MODULATION OF THE CELLULAR INHIBITANT OF THE APOPTOSIS EXPRESSION
EP2527442A3 (en)	2013-03-06	Compounds and methods for modulating gene expression
WO2005039480A8 (en)	2006-06-15	AChE ANTISENSE DEOXYOLIGONUCLEOTIDE AS AN ANTI-INFLAMMATORY AGENT
EP1248635A4 (en)	2004-12-08	ANTISENSE MODULATION OF THE GLYCOGEN SYNTHASE-KINASE-3ALPHA EXPRESSION
IL164674A (en)	2012-01-31	Catalytic deoxyribonucleic acid that cleaves pai-1 and uses thereof
DK1537210T3 (da)	2006-09-18	Decoy-oligonukleotid-inhibering af CD40-ekspression
NZ741086B2 (en)	2024-02-27	Compositions and methods for inhibiting gene expression of lpa
WO2004035759A3 (en)	2005-03-31	Inhibitory oligonucleotides targeted to matrix metalloproteinase-9